A Different Approach to Validating Screening Assays for Developmental Toxicity

被引:43
作者
Daston, George P. [1 ]
Chapin, Robert E. [2 ]
Scialli, Anthony R. [3 ]
Piersma, Aldert H. [4 ]
Carney, Edward W. [5 ]
Rogers, John M. [6 ]
Friedman, Jan M. [7 ,8 ]
机构
[1] Procter & Gamble Co, Cincinnati, OH 45202 USA
[2] Pfizer Global R&D, Groton, CT USA
[3] Tetra Tech Sci, Arlington, VA USA
[4] RIVM, Bilthoven, Netherlands
[5] Dow Chem Co USA, Midland, MI 48674 USA
[6] US EPA, Tox Assessment Div, NHEERL, ORD, Res Triangle Pk, NC 27711 USA
[7] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada
[8] Child & Family Res Inst, Vancouver, BC, Canada
关键词
in vitro methods; validation; developmental toxicity; VITRO EMBRYOTOXICITY TESTS; IN-VITRO; EMBRYO CULTURE; RAT; PREDICTION; CHEMICALS; SELECTION; WORKSHOP;
D O I
10.1002/bdrb.20276
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: There continue to be many efforts around the world to develop assays that are shorter than the traditional embryofetal developmental toxicity assay, or use fewer or no mammals, or use less compound, or have all three attributes. Each assay developer needs to test the putative assay against a set of performance standards, which traditionally has involved testing the assays against a list of compounds that are generally recognized as "positive'' or "negative'' in vivo. However, developmental toxicity is highly conditional, being particularly dependent on magnitude (i.e. dose) and timing of exposure, which makes it difficult to develop lists of compounds neatly assigned as developmental toxicants or not. APPROACH: Here we offer an alternative approach for the evaluation of developmental toxicity assays based on exposures. Exposures are classified as "positive'' or "negative'' in a system, depending on the compound and the internal concentration. Although this linkage to "internal dose'' departs from the recent approaches to validation, it fits well with widely accepted principles of developmental toxicology. CONCLUSIONS: This paper introduces this concept, discusses some of the benefits and drawbacks of such an approach, and lays out the steps we propose to implement it for the evaluation of developmental toxicity assays. Birth Defects Res (Part B) 89: 526-530, 2010. (C) 2010 Wiley-Liss, Inc.
引用
收藏
页码:526 / 530
页数:5
相关论文
共 18 条